DBVT - DBV Technologies provides update on investigational Viaskin(TM) Peanut

DBV Technologies (DBVT) rallies as it announced the receipt of written responses from the FDA to questions provided in the Type A meeting request the Co. submitted in October 2020.The Type A meeting request is for Biologics License Application for Viaskin™ Peanut, an investigational, non-invasive, once-daily epicutaneous patch to treat peanut allergy in children ages 4-11 years.DBV plans to initiate the selection of modified prototype patches in the first quarter of 2021."We are very encouraged by the positive feedback received from the FDA, and we appreciate the clarity provided,” stated Daniel Tassé, CEO.DBVT +28.07% AH to $4.79.

For further details see:

DBV Technologies provides update on investigational Viaskin™ Peanut